Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 6,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: 'KnowIt', 'OnTrack'; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 19 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neoplasms
Interventions: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more

Conditions: Cancer
Interventions: GSK2118436, Midazolam; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more

Conditions: Esophageal Achalasia, Esophageal Spasm, Diffuse, Esophageal Motility Disorders
Interventions: peroral endoscopic myotomy, Botulinum toxin injection; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Ambulation Difficulty, Lower Extremity Problem
Interventions: Gigstride Ambulatory Device; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ECRB Tendinopathy
Interventions: Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections; Device · Other
Lead sponsor: INCREDIWEAR HOLDINGS, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Zika, Zika Virus Infection
Interventions: VLA1601, CpG 1018®, 3M-052-AF; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more

Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Interventions: CGT9486, Sunitinib, Midazolam; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more

Conditions: Gastric Cancer
Interventions: cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 30
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more

Conditions: Nicotine Dependence
Interventions: Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing; Device · Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Oprozomib, Sorafenib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Burlington, California • Denver, Colorado • Miami, Florida + 3 more

Conditions: Lung Cancer
Interventions: Ruxolitinib, Erlotinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Advanced Solid Tumors
Interventions: TEV-56278, Pembrolizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • Lake Mary, Florida • Chicago, Illinois + 7 more

Conditions: Major Depressive Disorder
Interventions: behavioral activation, treatment-as-usual; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more

Conditions: Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Interventions: ABBV-637, Docetaxel, Osimertinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • Huntersville, North Carolina + 3 more

Conditions: Absorption; Chemicals, Sunscreening Agents
Interventions: Bemotrizinol; Drug
Lead sponsor: dsm-firmenich Switzerland AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
Interventions: Avapritinib, Decitabine, Decitabine/Cedazuridine; Drug · Combination Product
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Phoenix, Arizona • Palo Alto, California • Tampa, Florida + 4 more

Conditions: TGCT
Interventions: Emactuzumab, Placebo; Drug
Lead sponsor: SynOx Therapeutics Limited; Industry
Eligibility: 12 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Beverly Hills, California • Los Angeles, California • Columbus, Ohio + 2 more

Conditions: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors
Interventions: INCB062079; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • New York, New York • Toledo, Ohio

Conditions: Hepatitis C
Interventions: BZF961, Ritonavir, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: San Diego, California • Orlando, Florida • San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: Selinexor, Dexamethasone; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Chronic Hip Pain
Interventions: MRI; Diagnostic Test
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Use Of Gigstride Device In Patients With Lower Extremity Deficit

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

Nicotine Withdrawal Symptoms and Smoking Relapse

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Feasibility of a Behavioral Activation Trial

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study

Avapritinib With Decitabine in Patients With SM-AHN

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

Selinexor Treatment of Refractory Myeloma

Maveric Magnetic Resonance Imaging Used to Study Detailed Bone Apposition and Fixation of the Stryker Trident II Tritanium System